Last reviewed · How we verify
Low-dose oxytocin
Low-dose oxytocin, developed by Ohio State University, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, leveraging the well-understood mechanism of oxytocin. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Low-dose oxytocin |
|---|---|
| Sponsor | Ohio State University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of the Effect of Carbetocin Versus Oxytocin in the Prevention of Postpartum Hemorrhage After Emergency Caesarean Section in Antenatal Low-risk Patients (NA)
- Low-Dose Versus High-Dose Oxytocin Dosing for Induction and Augmentation of Labor (PHASE4)
- Comparing High Versus Low Dose of Oxytocin, in Gravida Women With BMI 30 and Above Which Are Undergoing Induction of Labor (PHASE4)
- Effect of Tafoxiparin on Cervical Ripening and Induction of Labor in Term Pregnant Women With an Unripe Cervix (PHASE2)
- A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine (PHASE2)
- Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls (NA)
- High Or Low Dose pOstpartUm Oxytocin at the Time of Cesarean Birth (PHASE2)
- Randomized Control Trial of Intracervical Balloon Placement vs Oxytocin in Women With Term PROM and Unripe Cervices (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low-dose oxytocin CI brief — competitive landscape report
- Low-dose oxytocin updates RSS · CI watch RSS
- Ohio State University portfolio CI